Positive outcome of the pivotal Phase III study with PQ Grass 27600 SU, a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine and Monophosphoryl Lipid A as adjuvant system

Positive outcome of the pivotal Phase III study with PQ Grass 27600 SU, a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine and Monophosphoryl Lipid A as adjuvant system

S. Zielen, J. A. Bernstein, U. Berger, M. Berger, R. Mösges, MH Shamji, LM DuBuske, M. Seybold, O. Armfield, K. Lis, K. Oluwayi, X. Pedragosa, M.F. Kramer, M.A. Skinner, P.J. de Kam; Session L-TPS09 - Allergen immunotherapy 7; EAACI 2024 Congress